Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance. The quarter saw substantial revenue growth, encouraging confidence in Gilead ...
Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results, a robust HIV franchise, and an imminent lenacapavir commercialization by summer 2025. Lenacapavir PrEP regimen, with 100% ...
Over the twelve months to December 2024, Gilead Sciences recorded an accrual ratio of -0.27. That implies it has very good cash conversion, and that its earnings in the last year actually ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback